Vortioxetine for Newly Diagnosed Glioblastoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
There is a very urgent need to improve on the currently limited treatment options for patients with glioblastoma. Despite extensive knowledge on the molecular pathogenesis of glioblastoma obtained through genomic, transcriptional and proteomic profiling, targeted therapy efforts have not yielded major advances, likely because of interindividual and intraindividual tumor heterogeneity and redundant oncogenic pathway activation. Accordingly, there is a strong rationale to approach the challenge of glioblastoma from a different angle, e.g., by ex vivo drug sensitivity profiling which is agnostic to the molecular profile of a tumor. This approach that we have termed "pharmacoscopy", has previously been explored in liquid cancers and probably led to improved patient outcomes. Using pharmacoscopy, the antidepressant drug, vortioxetine, has been identified as a lead candidate for further exploration in patients with glioblastoma. Vortioxetine also demonstrated synergistic anti-glioma activity in combination with temozolomide or lomustine. The ReVoGlio trial aims at demonstrating that vortioxetine, a drug selected based on ex vivo drug profiling (pharmacoscopy), is of benefit for patients with newly diagnosed glioblastoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Osoby w wieku 18 lat lub starsze.
- •Pacjenci z potwierdzonym histologicznie nowo zdiagnozowanym glejakiem (typ guza mózgu).
- •Stan ogólny pacjenta pozwala na standardowe leczenie (oceniany w skali Karnofsky'ego wynoszącej 70% lub więcej).
- •Pacjenci, którzy będą leczeni standardową radiochemioterapią (radioterapia z jednoczesną chemioterapią temozolomidem, a następnie dalsza chemioterapia temozolomidem).
- •Pacjentki w wieku rozrodczym muszą stosować skuteczną antykoncepcję lub mieć negatywny test ciążowy.
- •Mężczyźni zdolni do ojcostwa muszą stosować skuteczne metody antykoncepcji.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
University Hospital Zurich
Zurich, Switzerland
Trial contact
Michael Weller, Prof. Dr. med.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.